决定赛道的并非“爆款”

Core Insights - The medical AI sector is transitioning from a "value validation" phase to a stage where significant buyers are emerging, particularly by the end of 2025 [1] - Recent contracts worth over 100 million yuan have been awarded to companies like iFlytek, Alipay, and Baidu for government medical projects, indicating a shift towards system-level procurement rather than individual hospital purchases [1] - The current primary payers for medical AI solutions are government and public healthcare systems, focusing on public investment and capability building rather than market-driven returns [1] Industry Trends - The emergence of large orders signifies the opening of the "first gate" for the commercialization of medical AI, moving from platform construction to deep usage [1] - Medical AI is still in a "slow variable" phase in terms of consumer and market-level engagement, with its value primarily in reducing system costs and improving service efficiency rather than generating new revenue [1] - The ability of AI to create measurable value in real medical scenarios will be crucial in determining the future landscape of this sector as it progresses beyond initial infrastructure development [1]